Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS

NCT06247917 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndrome With Excess Blasts-1
Myelodysplastic Syndrome With Excess Blasts-2
Myelodysplastic Syndromes

Interventions

DRUG: Fludarabine, Busulfan and Melphalan

Sponsor

Ruijin Hospital